AzTrials
AzTrials

Enterocolitis, NecrotizingNCT05335577

Role of Urinary Claudin-2, Caveolin-1, and EGF as Diagnostic Biomarkers of Necrotizing Enterocolitis in Preterm Neonates

An observational study of Enterocolitis, Necrotizing and Infant, Premature, run by University of Brawijaya at 1 site in Indonesia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Our study aims to determine the differences in the concentration of urinary claudin-2, caveolin-1, and epidermal growth factor (EGF) as non-invasive biomarkers in the diagnosis of Necrotizing Enterocolitis (NEC). Read more about this study

Who is it for?
Ages 1 day to 28 daysHealthy volunteers can take part
Conditions the study is for
Enterocolitis, Necrotizing, Infant, Premature
What is being tested?
Urinary Claudin-2, Urinary Caveolin-1 and Urinary EGF
How many people
30 participants
Where
1 siteIndonesia
Study dates
17 Mar 2022to Jul 2022
How long will I take part?
7 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 28 days
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: The target population of this study are neonates that would be categorized into three groups, i.e. preterm neonates with NEC, without NEC, and healthy term infants. The subjects are recruited from Perinatology Unit, Saiful Anwar General Hospital from March-May 2022.

Who may be able to join

  • Premature neonates with 28-34 weeks' gestational age
  • Admitted in Perinatology Unit, Saiful Anwar General Hospital, Malang
  • Parents/guardians have agreed and signed the informed consent of the study
  • Neonates receive nutrition from breast milk or breast milk predominance
  • NEC was diagnosed using Bell's modification criteria.
  • Premature neonates with 28-34 weeks' gestational age, admitted in Perinatology Unit, Saiful Anwar General Hospital, Malang. Parents/guardians have agreed and signed the informed consent of the study. Neonates receive nutrition from breast milk or breast milk predominance.
  • Term neonates with 37-42 weeks' gestational age, admitted in Perinatology Unit, Saiful Anwar General Hospital, Malang. Parents/guardians have agreed and signed the informed consent of the study. Neonates receive nutrition from breast milk or breast milk predominance.

Who cannot join

  • Treated neonates who died during the study before the diagnosis of NEC was established
  • Neonates whom require surgery during the study
  • Parents/guardians stated that they were not willing to participate in the study.

Trial locations and contacts

1 site in 1 country.

Brigitta IRV Corebima, M.D.(Paed) contact

+62821-4056-2689

briggita_vebi@ub.ac.id

Indonesia1 site, 1 recruiting
  • Saiful Anwar General Hospital

    Malang, East Java, 65111

    Brigitta IRV Corebima, M.D.(Paed), +62821-4056-2689, briggita_vebi@ub.ac.id

    Brigitta IRV Corebima, M.D.(Paed)

    Recruiting

Other trials in Indonesia

About this study

Official title: Concentrations of Urinary Claudin-2, Caveolin-1, and Epidermal Growth Factor (EGF) as the Prototypes of Non-Invasive Biomarkers in the Diagnosis of Necrotizing Enterocolitis in Preterm Neonates

Our study aims to determine the differences in the concentration of urinary claudin-2, caveolin-1, and epidermal growth factor (EGF) as non-invasive biomarkers in the diagnosis of Necrotizing Enterocolitis (NEC). We compare the concentration of urinary claudin-2, caveolin-1, and EGF between preterm neonates at risk of NEC and healthy term infants as the basis for determining NEC biomarkers with the most optimum sensitivity and specificity. This analytical observational study is based on biomolecular profiling with a prospective cohort design approach. The research subjects are a group of preterm neonates (gestational age of 28-34 weeks) who were admitted in Perinatology Unit, Department of Pediatrics, Saiful Anwar General Hospital, Malang and whom diagnosed with NEC using Bell's criteria and serum TGF-β levels. Subjects are selected by consecutive sampling and single-blind analysis was performed in the Laboratory of Bioscience and Biomedicine, Faculty of Medicine, University of Brawijaya.

During the research process, groups of preterm and term neonates would be observed and their clinical development followed. The collection of biologic samples would be taking 10 cc of urine and 40 mg of feces on day-5 (D5) and 7 (D7). The consecutive manner of urinary sampling was regarded to assess whether there was a time-related protein expression in the course of the NEC process. Faecal samples would be assessed for microbiota profile analysis described by the ratio of Proteobacteria: Firmicutes and Bacteroidetes to represent dysbiosis process in NEC. After 7 days, the subjects would be grouped into a group of preterm neonates with NEC, a group of healthy term neonates as a control, while a group of preterm infants at whom during the course of the study did not develop NEC, would be assigned to group of premature neonates without NEC.

Urinary protein concentrations from the three groups would then be analyzed and adjusted with normalized creatinine, so that the levels of these three proteins could be assessed quantitatively using the ELISA (Enzyme-Linked Immunosorbent Assay) method. The results would be compared with the microbiota profile as the golden standard for NEC cases. Through statistical tests, sensitivity, specificity and cut-off of selected protein levels would be assessed as diagnostic biomarkers of NEC.

Read the detailed description

Necrotizing enterocolitis (NEC) is a multifactorial syndrome of acute intestinal ischemic necrosis which is one of the acute intestinal emergencies in neonates with high morbidity and mortality rates were higher in preterm. Inflammation and ischemia are the main pathogenesis of NEC. The diagnosis of NEC is established based on the demographic condition and clinical presentations, and further confirmed by the presence of pneumatosis intestinalis on plain abdominal radiographs. However, the clinical symptoms of NEC were often overlapped with other cases, especially diseases related to inflammation and sepsis, and the limitations of diagnostic methods both clinically and radiologically in identifying the early phase of NEC, make biomarker studies continue to be carried out to find diagnostic methods that would be able to predict, diagnose and differentiate NEC from non-NEC cases in a timely manner. Thus, a diagnostic method with high sensitivity and specificity is needed in cases of NEC in premature infants.

Several studies have shown that the immaturity of the gastrointestinal tract is related to the condition of the gastrointestinal cell barrier in infants who are susceptible to disintegration. The disruption in the expression of various proteins that make up the gastrointestinal tight junction in NEC, makes the tight junction protein component suspected to be a potential biomarker in the early phase of NEC. This is closely related to the presence of the inflammatory process of the NEC. Inflammatory conditions disrupt intestinal microcirculation, which results in the emergence of intestinal ischemia, and trigger the degradation of the tight junction components of the gastrointestinal tract through urine. This degradation process occurs in the early phase of the NEC disease course.

Several animal studies have shown that there is a correlation between abnormal expression of the proteins claudin-2, caveolin-1, and EGF and tight junction damage in NEC. Meanwhile, studies with a small number of neonates showed that the protein component is expressed in urine as a biomarker of tight junction damage in NEC and is independent of other inflammatory components, so that it is considered as a potential diagnostic biomarker in NEC cases.

This study aims to determine the differences in the expression of urinary claudin-2, caveolin-1, and EGF with NEC in preterm neonates at risk of NEC compared to healthy term infants as a basis for determining NEC biomarkers with optimum sensitivity and specificity, which then would be used as biomarker. The study was conducted using a cohort prospective method. The research subjects are a group of preterm neonates (gestational age of 28-34 weeks) who were admitted in Perinatology Unit, Department of Pediatrics, Saiful Anwar General Hospital, Malang and whom diagnosed with NEC using Bell's criteria and serum TGF-β levels obtained at Day-1 (D1). Subjects are selected by consecutive sampling and single-blind analysis was performed in the Laboratory of Bioscience and Biomedicine, Faculty of Medicine, University of Brawijaya.

During the research process, groups of preterm and term neonates would be observed and their clinical development followed. The collection of biologic samples would be taking 10 cc of urine and 40 mg of feces on day-5 (D5) and 7 (D7). The consecutive manner of urinary sampling was regarded to assess whether there was a time-related protein expression in the course of the NEC process. Faecal samples would be assessed for microbiota profile analysis described by the ratio of Proteobacteria: Firmicutes and Bacteroidetes to represent dysbiosis process in NEC. After 7 days, the subjects would be grouped into a group of preterm neonates with NEC, a group of healthy term neonates as a control, while a group of preterm infants at whom during the course of the study did not develop NEC, would be assigned to group of premature neonates without NEC.

Urinary protein concentrations from the three groups would then be analyzed and adjusted with normalized creatinine, so that the levels of these three proteins could be assessed quantitatively using the ELISA (Enzyme-Linked Immunosorbent Assay) method. The results would be compared with the microbiota profile as the golden standard for NEC cases. Through statistical tests, sensitivity, specificity and cut-off of selected protein levels would be assessed as prototype of diagnostic biomarkers in establishing NEC.

Sample size in this study was calculated by ANOVA repeated measure statistical analysis with a significance level of 0.05 and study power of 0.8. From the calculation, the subject needed is 10 patients for each group (total 30 subjects). The basic characteristics of the patient will be analyzed descriptively. All parameter data will be analyzed statistically by Statistical Product and Service Solution (SPSS) 20, preceded by normality test and homogeneity test. The study analysis will be sensitivity, specificity and cut-off of selected protein levels would be assessed as prototype of diagnostic biomarkers in establishing NEC. Further bivariate and multivariate analysis would be performed. Data transformation will be performed if needed in case of outlier data or out-of-range results.

Being tested
Urinary Claudin-2, Urinary Caveolin-1, Urinary EGF
Keywords
Necrotizing enterocolitis, Preterm neonates, Claudin-2, Caveolin-1, Epidermal growth factor, Bell's Criteria
Medical subject headings
Enterocolitis, Necrotizing, Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Urinary Claudin-2Diagnostic test

    A sequential non-invasive urinary molecular profiling for protein, i.e. Claudin-2 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

  • Urinary Caveolin-1Diagnostic test

    A sequential non-invasive urinary molecular profiling for protein, i.e. Caveolin-1 as potential marker for enterocyte tight junction disruption, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity and specificity.

  • Urinary EGFDiagnostic test

    A sequential non-invasive urinary molecular profiling for protein, i.e. epidermal growth factor (EGF) as potential marker for tight junction protective regulator, would be analyzed quantitatively with ELISA and then compared between groups to assess the optimum sensitivity.

Study groups in NCT05335577
Study groupRoleWhat they receive
Preterm neonates with NECPreterm neonates with gestational age of 28-32 weeks and diagnosed with Necrotizing Enterocolitis based on Bell's modification criteria.
Receives: Diagnostic Test: Urinary Claudin-2; Diagnostic Test: Urinary Caveolin-1; Diagnostic Test: Urinary EGF
Preterm neonates without NECPreterm neonates with gestational age of 28-32 weeks and without Necrotizing Enterocolitis based on Bell's modification criteria.
Receives: Diagnostic Test: Urinary Claudin-2; Diagnostic Test: Urinary Caveolin-1; Diagnostic Test: Urinary EGF
Healthy term neonatesTerm neonates with gestational age of 37-42 weeks without any comorbidities.
Receives: Diagnostic Test: Urinary Claudin-2; Diagnostic Test: Urinary Caveolin-1; Diagnostic Test: Urinary EGF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change of Urinary Claudin-2 Concentration

    Concentrations of claudin-2 protein on Day-5 and Day-7 identified in the urine of neonates with necrotizing enterocolitis (NEC), stated numerically in ng/ml.

    Measured: Day-5 and Day-7 of age

  2. Change of Urinary Caveolin-1 Concentration

    Concentrations of caveolin-1 protein on Day-5 and Day-7 identified in the urine of neonates with necrotizing enterocolitis (NEC), stated numerically in pg/ml.

    Measured: Day-5 and Day-7 of age

  3. Change of Urinary EGF Concentration

    Concentrations of EGF protein on Day-5 and Day-7 identified in the urine of neonates with necrotizing enterocolitis (NEC), stated numerically in pg/ml.

    Measured: Day-5 and Day-7 of age

  4. Bell's stage of NEC

    Bell's stage of NEC are categorized into stage IIa, IIb, IIIa, and IIIb.

    Measured: Day-1 (Baseline)

Secondary outcomes (3)
  1. Change of fecal microbiota profile

    Ratio copy number of DNA/ml feces for Proteobacteria:Firmicutes-Bacteroidetes, measured consecutively.

    Measured: Day-5 and Day-7 of age

  2. Change of Urinary Normalized Creatinine Level

    This creatinine concentration is used to normalize urinary claudin-2, caveolin-1, or EGF concentrations for ELISA.

    Measured: Day-5 and Day-7 of age

  3. Serum TGF-β Concentration

    Pre-existing study of TGF-β Concentration in preterm with NEC.

    Measured: Day-1 (Baseline)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Apr 2022
  2. Study start17 Mar 2022
  3. Primary completionMay 2022 (estimated)
  4. Study completionJul 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
Target duration
7 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT05335577
Sponsor's protocol ID
400/011/K.3/302/2022
Status last verified
Apr 2022
First submitted
12 Apr 2022
Last updated
19 Apr 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: The research team would like to discuss to what extent and the criteria of individual participant data that will be shared related to Statistical Analysis Plan, Informed Consent Form and/or Clinical Study Report.

Questions about this trial

What is this clinical trial studying?

An observational study of Enterocolitis, Necrotizing and Infant, Premature, run by University of Brawijaya at 1 site in Indonesia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Indonesia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Brigitta IRV Corebima, M.D.(Paed) (+62821-4056-2689, briggita_vebi@ub.ac.id), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change of Urinary Claudin-2 Concentration (time frame: Day-5 and Day-7 of age). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in